Drug Trial Radar · NCT07307794
To Evaluate the Adhesion of TK-254RX on Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jan 19, 2026
Primary completion
Mar 3, 2026
Study completion Mar 12, 2026
Sponsor
- Lead sponsor
- Teikoku Seiyaku Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH; Clinsearch GmbH; CRM Biometrics GmbH
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, multiple-dose trial in healthy participants. The primary purpose of this study is to assess the adhesion of TK-254RX. Secondary purposes are to assess the safety of TK-254RX and the residual amount of the patch.
Conditions
- Healthy Participants
Interventions
Esflurbiprofen Topical SystemDrug
The total of one TK-254RX per day for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterization of the patch adhesionTime frame: Day 1 to Day 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Deutsche Sporthochschule Köln
Am Sportpark Muengersdorf 6, Clogne, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.